Mucinous cancer of the appendix: Challenges in diagnosis and treatment

Journal of Chemotherapy

Volumn 19, Issue 4, 2007, Pages 451-454

  Andreopoulou, E ^a   Yee, H ^a   Warycha, M A ^a   Macari, M ^a   Berman, R ^a   Lowy, A ^b   Muggia, F ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Cetuximab; Cytoreductive surgery; Mucinous adenocarcinoma

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN; TUMOR MARKER;

AGED; ANAMNESIS; APPENDIX CARCINOMA; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; FEMALE; GENE CONTROL; HUMAN; HYPERTHERMIC THERAPY; IN SITU HYBRIDIZATION; LOADING DRUG DOSE; MUCINOUS CARCINOMA; PARACENTESIS; PERITONEUM METASTASIS; SKIN TOXICITY;

EID: 34547742648     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.4.451     Document Type: Article

References (23)

1. Chang P, Attiyeh FF. Adenocarcinoma of the appendix. Dis Colon Rectum 1981;24:176-.180.
2. Collins DC. 71,000 human appendix specimens: a final report, summarizing forty years' study. Am J Proctol. 1963; 14: 365-381.
3. McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix, a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002;94:3307-12.
4. Nitecki SS, Wolff BG, Schlinkert R, Sarr M. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994;219:51-7.
5. Andreopoulou E, Muggia F, Safa M, et al. Phase II study of cetuximab in mucinous peritoneal carcinomatosis JCO, 2006 Proc ASC024;625s (abstract 14020).
6. Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res. 2001; 2 (2): 85-9.
7. Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci USA. 1999; 96 (6): 3081-6.
8. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem. 2002;277(35):32258-67.
9. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6(8):727-31.
10. Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer. 1976;37(4): 1891-1900.
11. Werth R. Klinische und Anatomische Untersuchungen zur Lehre von den Bauchgeschwullsten und ver Laparotomie. Arch Gynecol Obstet 1884;24: 100-18.
12. Sugarbaker PH, Ronnett BM, Archer A. Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30: 233-80.
13. Sugarbaker PH. Are there curative options to peritoneal carcinomatosis? Ann Surg. 2005;242(5):748-50.
14. Carmignani CP, Hampton R, Sugarbaker CE, Dang P, Sugarbaker PH. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87(4):162-6.
15. Andreopoulou E, Lowy A, Newman E, Downey A, Safa M, Escalon J, Muggia F. Cetuximab in mucinous peritoneal carcinomatosis: assessment by serial CA19.9 and CEA measurements. AACR poster, 2007.
16. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219(2):112-9.
17. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005; 10 (2): 112-22.
18. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21 (20): 3737-43.
19. Elias D, Matsuhisa T, Sideris L, Liberate G, Drouard-Troalen L, Raynard B, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15(10):1558-65.
20. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993;113(6):631-6.
21. Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77(12):2622-9.
22. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85(2):61-7.
23. Levitz JS, Sugarbaker PH, Lichtman SM, Brun EA. Unusual abdominal tumors, case 1. Pseudomyxoma peritonei: response to capecitabine. J Clin Oncol 2004;22(8):1518-20.